A Phase 1a Study Evaluating the Safety, Tolerability, and Efficacy of IBI322 in Subjects With Advanced Cancers
Clinical trial NCT04338659 · COMPLETED
Trial details
- NCT number
- NCT04338659
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-01-14
- Primary completion
- 2023-02-28
- Enrollment
- 22
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.